Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$17.39 ▲ +1.33
(+8.28%)
MKT CAP: $1.65B • VOL: 5.15M
52W L $2 52W H $18
ROARABLE / RQD
D • 46/100
PIOTROSKI
3 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$15
MEDIAN
$19
MEAN
$20
HIGH
$24
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE REPL TAPE
REPL // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $21.04 | $20.00 | 2025-02-14 | $15.82 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $21.91 | $20.52 | 2025-02-06 | $16.35 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $19.82 | $19.13 | 2025-01-29 | $16.69 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $17.74 | — | 2025-01-17 | $17.04 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $15.30 | $16.52 | 2025-01-09 | $15.48 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $20.69 | $18.09 | 2024-12-18 | $15.13 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $16.87 | $17.56 | 2024-12-04 | $16.17 | -4.3% | 48% | C |